New Drug of Last Resort Tackles Resistant HIV | myHIVteam

Connect with others who understand.

sign up Log in
Resources
About myHIVteam
Powered By

New Drug of Last Resort Tackles Resistant HIV

Posted on December 20, 2018


By Serena Gordon, HealthDay Reporter

THURSDAY, Aug. 16, 2018 (HealthDay News) -- HIV, the virus that causes AIDS, is typically a manageable infection, but medications that keep the virus at bay don't work for everyone. Now, researchers have developed a new medication to help them.

The U.S. Food and Drug Administration approved the drug -- ibalizumab (Trogarzo) -- in March. Phase 3 trial results were published in the Aug. 16 issue of the New England Journal of Medicine.
"For those who have exhausted their current [drug] regimen, we now have another hope," the study's senior author, Dr. Stanley Lewis, said of the new drug. He's chief medical officer for TaiMed Biologics, maker of the drug and sponsor of the trial.

"HIV is probably the most dynamic pathogen in medicine. It's been a challenge to stay one step ahead of it," Lewis said.

The new drug is called a monoclonal antibody. It works by binding to receptors on CD4 cells. (CD4 is a type of immune system cell also known as T cells.) This blocks the virus from entering CD4 cells.

In an editorial accompanying the study, the FDA's Dr. Virginia Sheikh and colleagues wrote that "patients with multidrug-resistant HIV infection are at risk for illness and death because of their limited remaining treatment options."

Because of these serious risks, the FDA allowed a streamlined clinical trial of ibalizumab.

The study included 40 adults with multidrug-resistant HIV-1 infection. More than half had been treated unsuccessfully with a median of 10 drugs.


The researchers observed for a week how well the study participants' current treatment regimens were working. Then they added ibalizumab. Eighty-three percent saw a reduction in the amount of HIV in their body (called "viral load"), the findings showed.

After the first week of ibalizumab, participants were given the drug once every two weeks for 25 weeks. Their drug regimens also were optimized to ensure they were getting at least one drug that the virus was sensitive to, according to Lewis.

At week 25, the drug successfully reduced patients' overall viral load. In fact, almost half had viral loads that were considered undetectable.

However, the drug did have side effects -- some serious.

More than 5 percent of patients reported having diarrhea, dizziness, nausea
and rash, Sheikh said.

One patient had "immune reconstitution inflammatory syndrome," or IRIS, which Lewis described as an immune system overreaction. HIV hampers the body's ability to respond to infections. With IRIS, that immune system response is out of balance and causes inflammation, he said. This side effect is temporary.

Four patients in the trial died; their deaths were believed to be related to the underlying HIV infection.

Sheikh said the FDA will continue to monitor side effects, and update safety information on drug labels as needed.

Both Lewis and Sheikh said it's possible that HIV will eventually develop resistance to ibalizumab, too.

Lewis said he doesn't know what the drug costs, but said it was expected to be in line with other monoclonal antibodies. He added that it would likely be cheaper than some other drugs in that class.


SOURCES: Stanley Lewis, M.D., chief medical officer, TaiMed Biologics, Irvine, Calif.; Virginia Sheikh, M.D., medical officer, Center for Drug Evaluation and Research, U.S. Food and Drug Administration; Aug. 16, 2018, New England Journal of Medicine
Copyright © 2018 All rights reserved.

Here are some questions and conversations from myHIVteam:

New Treatment?

How do any of you manage to stay on medication and take them on time?

How is exercising with HIV or while taking ART?

Has antiretroviral therapy helped you successfully reduce your viral load?
Share in the comments below or directly on myHIVteam.

Posted on December 20, 2018
All updates must be accompanied by text or a picture.

We'd love to hear from you! Please share your name and email to post and read comments.

You'll also get the latest articles directly to your inbox.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Related Articles

If you take antiretroviral therapy (ART) to treat HIV, you may wonder how to manage your medicati...

HIV Meds in Different Time Zones: Taking Pills While Traveling

If you take antiretroviral therapy (ART) to treat HIV, you may wonder how to manage your medicati...
Modern antiretroviral therapy (ART) — the term for HIV treatment regimens — has come a long way o...

Injectables for HIV Treatment and Prevention: How They Work

Modern antiretroviral therapy (ART) — the term for HIV treatment regimens — has come a long way o...
If you or a loved one is taking antiretroviral therapy (ART) for HIV, you’ve probably heard about...

HIV Drug Resistance: Mutations, Testing, Symptoms, and More

If you or a loved one is taking antiretroviral therapy (ART) for HIV, you’ve probably heard about...
For people who have access to HIV medication and take it every day, as directed, HIV usually beco...

Treatment for HIV

For people who have access to HIV medication and take it every day, as directed, HIV usually beco...
If you’re living with HIV, you may wonder about the risks and benefits of using marijuana or cann...

Medical Marijuana and HIV: Can It Help?

If you’re living with HIV, you may wonder about the risks and benefits of using marijuana or cann...
Post-exposure prophylaxis (PEP) refers to medication that’s taken after a potential exposure to h...

Understanding PEP Side Effects, Plus Tips for Taking PEP

Post-exposure prophylaxis (PEP) refers to medication that’s taken after a potential exposure to h...

Recent Articles

Humberto Orozco is a graduate student, an athlete, and an advocate for people living with HIV. A...

Overcoming HIV Stigma: How I Found Self-Acceptance and Became an Advocate

Humberto Orozco is a graduate student, an athlete, and an advocate for people living with HIV. A...
Cuando se vive con el VIH, mantener una dieta saludable desempeña un papel importante en su biene...

HIV Diet: 7 Ways Latin Foods Can Help

Cuando se vive con el VIH, mantener una dieta saludable desempeña un papel importante en su biene...
MyHealthTeam does not provide health services, and if you need help, we’d strongly encourage you ...

Crisis Resources

MyHealthTeam does not provide health services, and if you need help, we’d strongly encourage you ...
Many people, including those living with human immunodeficiency virus (HIV), would like to help o...

Can You Donate Blood, Plasma, or Organs With Undetectable HIV?

Many people, including those living with human immunodeficiency virus (HIV), would like to help o...
Dating while living with the human immunodeficiency virus (HIV) can present unique challenges, bu...

Dating and HIV: 5 Tips and When To Disclose HIV Status

Dating while living with the human immunodeficiency virus (HIV) can present unique challenges, bu...
If you’re living with the human immunodeficiency virus (HIV), it’s important to remember that an ...

7 Incredible Athletes With HIV

If you’re living with the human immunodeficiency virus (HIV), it’s important to remember that an ...
myHIVteam My HIV Team

Thank you for subscribing!

Become a member to get even more:

sign up for free

close